NASDAQ:ILMN Illumina (ILMN) Stock Price, News & Analysis $144.41 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$144.40 -0.01 (-0.01%) As of 05/22/2026 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Illumina Stock (NASDAQ:ILMN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Illumina alerts:Sign Up Key Stats Today's Range$143.17▼$146.4950-Day Range$115.56▼$145.7052-Week Range$78.55▼$155.53Volume906,001 shsAverage Volume1.71 million shsMarket Capitalization$21.85 billionP/E Ratio26.26Dividend YieldN/APrice Target$137.75Consensus RatingHold Company Overview Illumina, Inc. (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications. The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays. Illumina also provides software and informatics solutions to support data analysis and workflow management, along with services and support for adoption of genomics in research and clinical settings. Its offerings are designed to address whole-genome, exome, transcriptome and targeted sequencing needs across discovery and diagnostic workflows. Illumina operates globally, selling products and services across the Americas, Europe, the Middle East, Africa and the Asia-Pacific region. Since its founding, the company has played a central role in lowering the cost and increasing the throughput of DNA sequencing, enabling broader use of genomic tools in research and medicine. Illumina’s strategy emphasizes technological innovation, partnerships and an executive leadership team and board that guide product development, commercial operations and regulatory and market access activities worldwide.AI Generated. May Contain Errors. Read More Illumina Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreILMN MarketRank™: Illumina scored higher than 65% of companies evaluated by MarketBeat, and ranked 296th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingIllumina has received a consensus rating of Hold. The company's average rating score is 2.28, and is based on no strong buy ratings, 7 buy ratings, 9 hold ratings, and 2 sell ratings.Upside/DownsideThe consensus price target for Illumina is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageIllumina has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Illumina's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth13.08% Earnings GrowthEarnings for Illumina are expected to grow by 13.08% in the coming year, from $5.20 to $5.88 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Illumina is 26.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.78.Price to Earnings Ratio vs. SectorThe P/E ratio of Illumina is 26.26, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.00.Price to Earnings Growth RatioIllumina has a PEG Ratio of 2.39. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIllumina has a P/B Ratio of 8.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Illumina's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.46% of the float of Illumina has been sold short.Short Interest Ratio / Days to CoverIllumina has a short interest ratio ("days to cover") of 4.68.Change versus previous monthShort interest in Illumina has recently decreased by 8.80%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIllumina does not currently pay a dividend.Dividend GrowthIllumina does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.91 News SentimentIllumina has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Illumina this week, compared to 9 articles on an average week.Search Interest16 people have searched for ILMN on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat Follows12 people have added Illumina to their MarketBeat watchlist in the last 30 days. This is an increase of 1,100% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Illumina insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $48,028,308.00 in company stock.Percentage Held by Insiders2.90% of the stock of Illumina is held by insiders.Percentage Held by Institutions89.42% of the stock of Illumina is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Illumina's insider trading history. Receive ILMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ILMN Stock News HeadlinesIllumina (ILMN) Valuation Check After Strong Recent Share Price MomentumMay 23 at 7:54 AM | finance.yahoo.comDavid P. King elected to Illumina's Board of DirectorsMay 21, 2026 | finance.yahoo.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 25 at 1:00 AM | Paradigm Press (Ad)David P. King elected to Illumina's Board of DirectorsMay 21, 2026 | prnewswire.comIs This the Right Time to Retain ILMN Stock in Your Portfolio?May 20, 2026 | finance.yahoo.com3 Reasons to Sell ILMN and 1 Stock to Buy InsteadMay 20, 2026 | finance.yahoo.comIllumina (NASDAQ:ILMN) Director Keith Meister Sells 104,393 SharesMay 15, 2026 | insidertrades.comIllumina (NASDAQ:ILMN) SVP Christensen Jakob Wedel Sells 700 SharesMay 8, 2026 | insidertrades.comSee More Headlines ILMN Stock Analysis - Frequently Asked Questions How have ILMN shares performed this year? Illumina's stock was trading at $131.16 on January 1st, 2026. Since then, ILMN shares have increased by 10.1% and is now trading at $144.41. How were Illumina's earnings last quarter? Illumina, Inc. (NASDAQ:ILMN) issued its quarterly earnings results on Thursday, April, 30th. The life sciences company reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.05 by $0.10. Illumina's revenue was up 4.8% on a year-over-year basis. Read the conference call transcript. Does Illumina have any subsidiaries? Illumina subsidiaries include Grail, Enancio, BlueBee, Edico Genome, Conexio Genomics, GenoLogics, NextBio, and more. Who are Illumina's major shareholders? Top institutional shareholders of Illumina include WCM Investment Management LLC (3.91%), Janus Henderson Group PLC (1.39%), Southpoint Capital Advisors LP (1.39%) and Senvest Management LLC (1.02%). Insiders that own company stock include Susan H Tousi, Scott M Davies, Patricia Leckman, Christensen Jakob Wedel, Jacob Thaysen, Scott Gottlieb and Aimee L Hoyt. View institutional ownership trends. How do I buy shares of Illumina? Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Illumina own? Based on aggregate information from My MarketBeat watchlists, some other companies that Illumina investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Visa (V) and Alphabet (GOOG). Company Calendar Last Earnings4/30/2026Today5/25/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 3 weeks, ILMN's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:ILMN CIK1110803 Webwww.illumina.com Phone(858) 202-4500Fax858-202-4766Employees8,650Year Founded1998Price Target and Rating Average Price Target for Illumina$137.75 High Price Target$170.00 Low Price Target$95.00 Potential Upside/Downside-4.6%Consensus RatingHold Rating Score (0-4)2.28 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)$5.50 Trailing P/E Ratio26.26 Forward P/E Ratio27.77 P/E Growth2.39Net Income$850 million Net Margins19.42% Pretax Margin24.15% Return on Equity31.01% Return on Assets12.22% Debt Debt-to-Equity Ratio0.56 Current Ratio1.75 Quick Ratio1.36 Sales & Book Value Annual Sales$4.34 billion Price / Sales5.03 Cash Flow$6.71 per share Price / Cash Flow21.51 Book Value$17.69 per share Price / Book8.16Miscellaneous Outstanding Shares151,300,000Free Float146,912,000Market Cap$21.85 billion OptionableOptionable Beta1.42 Social Links 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:ILMN) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Illumina, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Illumina With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
